NEW YORK (GenomeWeb) – CRISPR/Cas9 gene editing firm Editas has filed a preliminary prospectus with US regulators for an initial public offering.

In its Form S-1, filed Monday with the US Securities and Exchange Commission, the Cambridge, Massachusetts-based company said that it plans to list on the Nasdaq Global Market under ticker symbol "EDIT."

The firm has not yet priced its shares or said how many shares it plans to offer. The IPO will be underwritten by Morgan Stanley, JP Morgan, Cowen and Company, and JMP Securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.